Get the Stockscreener App
5.28
3.53%
0.18
After Hours:
5.31
0.03
+0.57%
Absci Corp stock is traded at $5.28, with a volume of 3.02M.
It is up +3.53% in the last 24 hours and up +34.01% over the past month.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
See More
Previous Close:
$5.10
Open:
$5.22
24h Volume:
3.02M
Relative Volume:
0.70
Market Cap:
$823.18M
Revenue:
$2.80M
Net Income/Loss:
$-115.18M
P/E Ratio:
-6.2316
EPS:
-0.8473
Net Cash Flow:
$-94.03M
1W Performance:
+14.04%
1M Performance:
+34.01%
6M Performance:
+70.87%
1Y Performance:
+98.50%
1-Day Range:
$5.16
$5.48
1-Week Range:
$4.66
$5.48
52-Week Range:
$2.24
$6.72
Absci Corp Stock (ABSI) Company Profile
Name
Absci Corp
Sector
Industry
Phone
(360) 949-1041
Address
18105 SE MILL PLAIN BLVD, VANCOUVER
Compare ABSI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
5.28 | 795.12M | 2.80M | -115.18M | -94.03M | -0.8473 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-02-25 | Initiated | JP Morgan | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jan-22-25 | Initiated | Needham | Buy |
| Oct-02-24 | Initiated | Guggenheim | Buy |
| Jul-03-24 | Initiated | Morgan Stanley | Overweight |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-04-23 | Initiated | H.C. Wainwright | Buy |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Jul-18-22 | Initiated | Truist | Buy |
| Mar-02-22 | Resumed | Cowen | Market Perform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Nov-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Aug-16-21 | Initiated | BofA Securities | Neutral |
| Aug-16-21 | Initiated | Cowen | Market Perform |
| Aug-16-21 | Initiated | Credit Suisse | Outperform |
| Aug-16-21 | Initiated | Stifel | Hold |
View All
Absci Corp Stock (ABSI) Latest News
CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy? - AOL.com
The 1 AI Stock I'd Put in a Time Capsule and Open in 2036 - AOL.com
Grail's Slump Enters Week 10. Is There Any End in Sight? - AOL.com
Doximity Stock Just Got Crushed. Is This a Rare Chance to Buy a High-Quality Growth Company on Sale? - AOL.com
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $11 - Moomoo
2 Stocks That Could Realistically Double by 2030 - AOL.com
ABSI Price Today: Absci Corporation Stock Price, Quote & Chart | MEXC - MEXC Exchange
Absci Insider Buyers Pleased With US$700k Return On Investment - Yahoo Finance
AI-driven drug developer Absci lines up Jefferies and Goldman talks - Stock Titan
Portland InnoAbsci's move into generative AI | Why former Hydro Flask CEO joined Puffin - The Business Journals
Morgan Stanley Trims Price Target on Absci to $4.10 From $4.20, Keeps Equalweight Rating - Moomoo
AMD Reveals A $6.5 Million Marvell Bet That's Already Soaring - Sahm
Insider Buying: Menelas Pangalos Acquires Shares in Absci Corp (ABSI) - GuruFocus
Absci Corp (ABSI) director Menelas Pangalos adds 37,453 shares in open-market buy - Stock Titan
AMD Reveals A $6.5 Million Marvell Bet That's Already Soaring - Benzinga
HC Wainwright Has Optimistic Outlook of Absci Q3 Earnings - MarketBeat
Absci price target raised to $11 from $9 at JonesResearch - TipRanks
TradingKey - TradingKey
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $11 - 富途牛牛
Earnings call transcript: Absci Corp misses revenue forecast in Q1 2026 - Investing.com UK
H.C. Wainwright Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Absci Corporation (ABSI) reports Q1 loss, misses revenue estimates - MSN
Absci Corp. Charts High-Stakes Path With ABS-201 - TipRanks
Needham Reiterates Buy Rating on ABSI with Price Target of $7.00 - GuruFocus
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Absci (NASDAQ:ABSI) Given New $11.00 Price Target at Truist Financial - MarketBeat
Absci’s ABS-201 Hair-Loss Trial Moves Forward: What Early-Stage Data Could Mean for ABSI - TipRanks
Absci (NASDAQ:ABSI) Shares Gap DownShould You Sell? - MarketBeat
Absci Shares Fall After 1Q Loss Widens - Moomoo
Truist Financial Maintains Absci Corp(ABSI.US) With Buy Rating, Announces Target Price $11 - 富途牛牛
Absci Corporation (NASDAQ:ABSI) Q1 2026 Earnings Call Transcript - Insider Monkey
12 Health Care Stocks Moving In Friday's Pre-Market SessionAbsci (NASDAQ:ABSI), Amylyx Pharmaceuticals - Benzinga
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results - The Manila Times
TD Cowen Maintains Absci Corp(ABSI.US) With Buy Rating - 富途牛牛
Absci (NASDAQ:ABSI) Releases Quarterly Earnings Results, Hits Estimates - MarketBeat
Absci reports Q1 EPS (19c), consensus (20c) - TipRanks
Earnings call transcript: Absci’s Q1 2026 revenue falls short, stock dips - Investing.com Nigeria
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings call transcript: Absci’s Q1 2026 revenue falls short, stock dips By Investing.com - Investing.com South Africa
Absci Corp (NASDAQ:ABSI) Plunges on 86% Q1 Revenue Miss Despite Clinical Advances - ChartMill
Absci Q1 Earnings Call Highlights - Yahoo Finance
Hair-loss drug trial reaches patient dosing; Absci adds ABS-202 - Stock Titan
Absci (ABSI) posts Q1 2026 results, advances ABS-201 and adds ABS-202 - Stock Titan
Absci (NASDAQ: ABSI) Q1 loss widens as revenue falls to $0.2M - Stock Titan
Absci : Corporate Presentation, May 2026 - marketscreener.com
Absci (ABSI) Q1 2026 Earnings Call Transcript - The Globe and Mail
Absci Corp Stock (ABSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Absci Corp Stock (ABSI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Busch Andreas | Chief Innovation Officer |
Mar 12 '26 |
Buy |
2.29 |
100,000 |
229,000 |
421,446 |
| Pangalos Menelas N | Director |
Feb 27 '26 |
Buy |
2.74 |
75,095 |
205,760 |
189,055 |
| McClain Sean | Chief Executive Officer |
Feb 23 '26 |
Option Exercise |
1.21 |
396,399 |
479,643 |
8,730,966 |
| McClain Sean | Chief Executive Officer |
Feb 02 '26 |
Sale |
2.99 |
26,761 |
80,015 |
8,334,567 |
| Jonasson Zachariah | CFO / CBO |
Feb 02 '26 |
Sale |
2.99 |
17,496 |
52,313 |
383,538 |
| VAN HOUTEN FRANS | Director |
Dec 05 '25 |
Buy |
3.72 |
40,000 |
148,800 |
63,320 |
| Pangalos Menelas N | Director |
Sep 22 '25 |
Buy |
2.66 |
95,785 |
254,788 |
113,960 |
| Bedrick Todd | SVP, CAO |
Sep 22 '25 |
Buy |
2.70 |
10,000 |
27,000 |
180,428 |
| Busch Andreas | Chief Innovation Officer |
Jul 28 '25 |
Buy |
3.04 |
50,000 |
152,000 |
327,264 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):